Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Nov;85(11):1706–1712. doi: 10.1054/bjoc.2001.2137

Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer

Y Shou 1,3, T Hirano 1, Y Gong 1, Y Kato 1,2, K Yoshida 1, T Ohira 1, N Ikeda 1, C Konaka 1, Y Ebihara 2, F Zhao 3, H Kato 1
PMCID: PMC2363988  PMID: 11742492

Abstract

We attempted to investigate immunohistochemical expression of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), platelet-derived growth factor (PD-ECGF), c-erbB-2, matrix metalloproteinase-2 (MMP-2), and MMP-9 using surgical specimens of 119 non-small-cell lung carcinoma (NSCLC) cases and to evaluate the relationship between the expression levels of each molecule and clinicopathological factors or prognosis. VEGF expression levels were significantly associated with the local invasion (P = 0.0001), lymph node involvement (pN-factor) (P = 0.0019), pathological stage (p-stage) (P = 0.0027) and lymphatic permeation (P = 0.0389). PD-ECGF expression levels were associated with pN-factor (P = 0.0347). MMP-2 expression levels were associated with pN-factor (P = 0.004) and lymphatic permeation (P = 0.0056). Also, MMP-9 expression levels showed a significant correlation to local invasion (P = 0.0012), pN-factor (P = 0.0093) and p-stage (P = 0.0142). Multivariate analysis showed VEGF to be the most related to local invasion (P = 0.0084), and MMP-2 was the only factor with significant independent impact on lymphatic permeation (P = 0.0228). Furthermore, log-rank analysis showed significant association with poor survival by VEGF, bFGF, MMP-2 and MMP-9. Especially, combined overexpression of VEGF and MMP-2 revealed poor prognosis, our study might provide a basis for the better evaluation of biological characteristics and a new therapeutic strategy based on chemotherapy. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: vascular endothelial growth, basic fibroblast growth factor, platelet-derived growth factor, matrix metalloproteinase-2, matrix metalloproteinase-9, non-small-cell lung carcinoma

Full Text

The Full Text of this article is available as a PDF (88.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aznavoorian S., Murphy A. N., Stetler-Stevenson W. G., Liotta L. A. Molecular aspects of tumor cell invasion and metastasis. Cancer. 1993 Feb 15;71(4):1368–1383. doi: 10.1002/1097-0142(19930215)71:4<1368::aid-cncr2820710432>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  2. Belotti D., Paganoni P., Giavazzi R. MMP inhibitors: experimental and clinical studies. Int J Biol Markers. 1999 Oct-Dec;14(4):232–238. doi: 10.1177/172460089901400406. [DOI] [PubMed] [Google Scholar]
  3. Bergers G., Brekken R., McMahon G., Vu T. H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000 Oct;2(10):737–744. doi: 10.1038/35036374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brown P. D., Bloxidge R. E., Stuart N. S., Gatter K. C., Carmichael J. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst. 1993 Apr 7;85(7):574–578. doi: 10.1093/jnci/85.7.574. [DOI] [PubMed] [Google Scholar]
  5. Cox G., Jones J. L., O'Byrne K. J. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res. 2000 Jun;6(6):2349–2355. [PubMed] [Google Scholar]
  6. Curran S., Murray G. I. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol. 1999 Nov;189(3):300–308. doi: 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  7. Duensing S., Grosse J., Atzpodien J. Increased serum levels of basic fibroblast growth factor (bFGF) are associated with progressive lung metastases in advanced renal cell carcinoma patients. Anticancer Res. 1995 Sep-Oct;15(5B):2331–2333. [PubMed] [Google Scholar]
  8. Folkman J. Tumor angiogenesis. Adv Cancer Res. 1985;43:175–203. doi: 10.1016/s0065-230x(08)60946-x. [DOI] [PubMed] [Google Scholar]
  9. Fontanini G., Vignati S., Boldrini L., Chinè S., Silvestri V., Lucchi M., Mussi A., Angeletti C. A., Bevilacqua G. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res. 1997 Jun;3(6):861–865. [PubMed] [Google Scholar]
  10. Fujise N., Nanashim A., Taniguchi Y., Matsuo S., Hatano K., Matsumoto Y., Tagawa Y., Ayabe H. Prognostic impact of cathepsin B and matrix metalloproteinase-9 in pulmonary adenocarcinomas by immunohistochemical study. Lung Cancer. 2000 Jan;27(1):19–26. doi: 10.1016/s0169-5002(99)00088-4. [DOI] [PubMed] [Google Scholar]
  11. Garzetti G. G., Ciavattini A., Lucarini G., Pugnaloni A., De Nictolis M., Amati S., Romanini C., Biagini G. Expression of vascular endothelial growth factor related to 72-kilodalton metalloproteinase immunostaining in patients with serous ovarian tumors. Cancer. 1999 May 15;85(10):2219–2225. doi: 10.1002/(sici)1097-0142(19990515)85:10<2219::aid-cncr17>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  12. Gasparini G. Angiogenesis research up to 1996. A commentary on the state of art and suggestions for future studies. Eur J Cancer. 1996 Dec;32A(14):2379–2385. doi: 10.1016/s0959-8049(96)00424-8. [DOI] [PubMed] [Google Scholar]
  13. Giani C., Casalini P., Pupa S. M., De Vecchi R., Ardini E., Colnaghi M. I., Giordano A., Ménard S. Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation. Oncogene. 1998 Jul 30;17(4):425–432. doi: 10.1038/sj.onc.1201954. [DOI] [PubMed] [Google Scholar]
  14. Giatromanolaki A., Gorgoulis V., Chetty R., Koukourakis M. I., Whitehouse R., Kittas C., Veslemes M., Gatter K. C., Iordanoglou I. C-erbB-2 oncoprotein expression in operable non-small cell lung cancer. Anticancer Res. 1996 Mar-Apr;16(2):987–993. [PubMed] [Google Scholar]
  15. Giatromanolaki A., Koukourakis M. I., Kakolyris S., Turley H., O'Byrne K., Scott P. A., Pezzella F., Georgoulias V., Harris A. L., Gatter K. C. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res. 1998 Dec;4(12):3017–3024. [PubMed] [Google Scholar]
  16. Ginsberg R. J., Rubinstein L. V. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995 Sep;60(3):615–623. doi: 10.1016/0003-4975(95)00537-u. [DOI] [PubMed] [Google Scholar]
  17. González-Avila G., Iturria C., Vadillo F., Terán L., Selman M., Pérez-Tamayo R. 72-kD (MMP-2) and 92-kD (MMP-9) type IV collagenase production and activity in different histologic types of lung cancer cells. Pathobiology. 1998;66(1):5–16. doi: 10.1159/000027989. [DOI] [PubMed] [Google Scholar]
  18. Guddo F., Fontanini G., Reina C., Vignola A. M., Angeletti A., Bonsignore G. The expression of basic fibroblast growth factor (bFGF) in tumor-associated stromal cells and vessels is inversely correlated with non-small cell lung cancer progression. Hum Pathol. 1999 Jul;30(7):788–794. doi: 10.1016/s0046-8177(99)90139-9. [DOI] [PubMed] [Google Scholar]
  19. Haas T. L., Davis S. J., Madri J. A. Three-dimensional type I collagen lattices induce coordinate expression of matrix metalloproteinases MT1-MMP and MMP-2 in microvascular endothelial cells. J Biol Chem. 1998 Feb 6;273(6):3604–3610. doi: 10.1074/jbc.273.6.3604. [DOI] [PubMed] [Google Scholar]
  20. Hengstler J. G., Lange J., Kett A., Dornhöfer N., Meinert R., Arand M., Knapstein P. G., Becker R., Oesch F., Tanner B. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer. Cancer Res. 1999 Jul 1;59(13):3206–3214. [PubMed] [Google Scholar]
  21. Hiraoka N., Allen E., Apel I. J., Gyetko M. R., Weiss S. J. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell. 1998 Oct 30;95(3):365–377. doi: 10.1016/s0092-8674(00)81768-7. [DOI] [PubMed] [Google Scholar]
  22. Hsu S. M., Raine L., Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981 Apr;29(4):577–580. doi: 10.1177/29.4.6166661. [DOI] [PubMed] [Google Scholar]
  23. Itoh T., Tanioka M., Yoshida H., Yoshioka T., Nishimoto H., Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 1998 Mar 1;58(5):1048–1051. [PubMed] [Google Scholar]
  24. Johnson L. L., Dyer R., Hupe D. J. Matrix metalloproteinases. Curr Opin Chem Biol. 1998 Aug;2(4):466–471. doi: 10.1016/s1367-5931(98)80122-1. [DOI] [PubMed] [Google Scholar]
  25. Kern J. A., Schwartz D. A., Nordberg J. E., Weiner D. B., Greene M. I., Torney L., Robinson R. A. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res. 1990 Aug 15;50(16):5184–5187. [PubMed] [Google Scholar]
  26. Kleiner D. E., Stetler-Stevenson W. G. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol. 1999;43 (Suppl):S42–S51. doi: 10.1007/s002800051097. [DOI] [PubMed] [Google Scholar]
  27. Kodate M., Kasai T., Hashimoto H., Yasumoto K., Iwata Y., Manabe H. Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung. Pathol Int. 1997 Jul;47(7):461–469. doi: 10.1111/j.1440-1827.1997.tb04525.x. [DOI] [PubMed] [Google Scholar]
  28. Kono T., Nishida M., Inagaki N., Tanaka Y., Yoneda M., Kasai S. Development and characterization of 1C6-203, a new monoclonal antibody specific to human thymidine phosphorylase. J Histochem Cytochem. 2001 Jan;49(1):131–138. doi: 10.1177/002215540104900113. [DOI] [PubMed] [Google Scholar]
  29. Koukourakis M. I., Giatromanolaki A., O'Byrne K. J., Comley M., Whitehouse R. M., Talbot D. C., Gatter K. C., Harris A. L. Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. Br J Cancer. 1997;75(4):477–481. doi: 10.1038/bjc.1997.83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Mountain C. F. Revisions in the International System for Staging Lung Cancer. Chest. 1997 Jun;111(6):1710–1717. doi: 10.1378/chest.111.6.1710. [DOI] [PubMed] [Google Scholar]
  31. Nelson A. R., Fingleton B., Rothenberg M. L., Matrisian L. M. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000 Mar;18(5):1135–1149. doi: 10.1200/JCO.2000.18.5.1135. [DOI] [PubMed] [Google Scholar]
  32. O'Byrne K. J., Koukourakis M. I., Giatromanolaki A., Cox G., Turley H., Steward W. P., Gatter K., Harris A. L. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer. 2000 Apr;82(8):1427–1432. doi: 10.1054/bjoc.1999.1129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Ohta M., Konno H., Tanaka T., Baba M., Kamiya K., Oba K., Kaneko T., Syouji T., Igarashi A., Nakamura S. Effect of combination therapy with matrix metalloproteinase inhibitor MMI-166 and mitomycin C on the growth and liver metastasis of human colon cancer. Jpn J Cancer Res. 2001 Jun;92(6):688–695. doi: 10.1111/j.1349-7006.2001.tb01149.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Ohta T., Yamamoto M., Numata M., Iseki S., Tsukioka Y., Miyashita T., Kayahara M., Nagakawa T., Miyazaki I., Nishikawa K. Expression of basic fibroblast growth factor and its receptor in human pancreatic carcinomas. Br J Cancer. 1995 Oct;72(4):824–831. doi: 10.1038/bjc.1995.420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Ohta Y., Tomita Y., Oda M., Watanabe S., Murakami S., Watanabe Y. Tumor angiogenesis and recurrence in stage I non-small cell lung cancer. Ann Thorac Surg. 1999 Sep;68(3):1034–1038. doi: 10.1016/s0003-4975(99)00611-6. [DOI] [PubMed] [Google Scholar]
  36. Ohta Y., Watanabe Y., Murakami S., Oda M., Hayashi Y., Nonomura A., Endo Y., Sasaki T. Vascular endothelial growth factor and lymph node metastasis in primary lung cancer. Br J Cancer. 1997;76(8):1041–1045. doi: 10.1038/bjc.1997.505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Oshika Y., Nakamura M., Tokunaga T., Ozeki Y., Fukushima Y., Hatanaka H., Abe Y., Yamazaki H., Kijima H., Tamaoki N. Expression of cell-associated isoform of vascular endothelial growth factor 189 and its prognostic relevance in non-small cell lung cancer. Int J Oncol. 1998 Mar;12(3):541–544. doi: 10.3892/ijo.12.3.541. [DOI] [PubMed] [Google Scholar]
  38. Passlick B., Sienel W., Seen-Hibler R., Wöckel W., Thetter O., Mutschler W., Pantel K. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res. 2000 Oct;6(10):3944–3948. [PubMed] [Google Scholar]
  39. Pfeiffer P., Clausen P. P., Andersen K., Rose C. Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer. 1996 Jul;74(1):86–91. doi: 10.1038/bjc.1996.320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Sato Y., Mukai K., Watanabe S., Goto M., Shimosato Y. The AMeX method. A simplified technique of tissue processing and paraffin embedding with improved preservation of antigens for immunostaining. Am J Pathol. 1986 Dec;125(3):431–435. [PMC free article] [PubMed] [Google Scholar]
  41. Slamon D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A., McGuire W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987 Jan 9;235(4785):177–182. doi: 10.1126/science.3798106. [DOI] [PubMed] [Google Scholar]
  42. Stetler-Stevenson W. G., Hewitt R., Corcoran M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol. 1996 Jun;7(3):147–154. doi: 10.1006/scbi.1996.0020. [DOI] [PubMed] [Google Scholar]
  43. Suzuki M., Iizasa T., Fujisawa T., Baba M., Yamaguchi Y., Kimura H., Suzuki H. Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in non-small-cell lung cancer. Invasion Metastasis. 1998;18(3):134–141. doi: 10.1159/000024506. [DOI] [PubMed] [Google Scholar]
  44. Takanami I., Tanaka F., Hashizume T., Kikuchi K., Yamamoto Y., Yamamoto T., Kodaira S. The basic fibroblast growth factor and its receptor in pulmonary adenocarcinomas: an investigation of their expression as prognostic markers. Eur J Cancer. 1996 Aug;32A(9):1504–1509. doi: 10.1016/0959-8049(95)00620-6. [DOI] [PubMed] [Google Scholar]
  45. Takebayashi Y., Akiyama S., Akiba S., Yamada K., Miyadera K., Sumizawa T., Yamada Y., Murata F., Aikou T. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst. 1996 Aug 21;88(16):1110–1117. doi: 10.1093/jnci/88.16.1110. [DOI] [PubMed] [Google Scholar]
  46. Tateishi M., Ishida T., Mitsudomi T., Kaneko S., Sugimachi K. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer. 1991;27(11):1372–1375. doi: 10.1016/0277-5379(91)90012-3. [DOI] [PubMed] [Google Scholar]
  47. Tsuda H., Hirohashi S., Shimosato Y., Hirota T., Tsugane S., Yamamoto H., Miyajima N., Toyoshima K., Yamamoto T., Yokota J. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res. 1989 Jun 1;49(11):3104–3108. [PubMed] [Google Scholar]
  48. Ueki T., Koji T., Tamiya S., Nakane P. K., Tsuneyoshi M. Expression of basic fibroblast growth factor and fibroblast growth factor receptor in advanced gastric carcinoma. J Pathol. 1995 Dec;177(4):353–361. doi: 10.1002/path.1711770405. [DOI] [PubMed] [Google Scholar]
  49. Volm M., Koomägi R., Mattern J. PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis. Anticancer Res. 1999 Jan-Feb;19(1B):651–655. [PubMed] [Google Scholar]
  50. Volm M., Koomägi R., Mattern J., Stammler G. Angiogenic growth factors and their receptors in non-small cell lung carcinomas and their relationships to drug response in vitro. Anticancer Res. 1997 Jan-Feb;17(1A):99–103. [PubMed] [Google Scholar]
  51. Wilson C. L., Matrisian L. M. Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol. 1996 Feb;28(2):123–136. doi: 10.1016/1357-2725(95)00121-2. [DOI] [PubMed] [Google Scholar]
  52. Yano T., Tanikawa S., Fujie T., Masutani M., Horie T. Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. Eur J Cancer. 2000 Mar;36(5):601–609. doi: 10.1016/s0959-8049(99)00327-5. [DOI] [PubMed] [Google Scholar]
  53. Zucker S., Cao J., Chen W. T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene. 2000 Dec 27;19(56):6642–6650. doi: 10.1038/sj.onc.1204097. [DOI] [PubMed] [Google Scholar]
  54. el-Torky M., el-Zeky F., Hall J. C. Significant changes in the distribution of histologic types of lung cancer. A review of 4928 cases. Cancer. 1990 May 15;65(10):2361–2367. doi: 10.1002/1097-0142(19900515)65:10<2361::aid-cncr2820651034>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES